[시장보고서]세계의 제네릭 종양학 의약품 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2033년)

세계의 제네릭 종양학 의약품 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2033년)

Generic Oncology Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

상품코드 : 1555609

리서치사 : Persistence Market Research

발행일 : 2024년 09월

페이지 정보 : 영문 176 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,211,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,532,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,265,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

Persistence Market Research는 세계 제네릭 종양학 의약품 시장에 대한 종합적인 보고서를 발표하고 시장 성장 촉진요인, 동향, 기회 및 과제를 포함한 주요 시장 역학을 자세히 분석했습니다. 이 보고서는 시장 구조와 성장 가능성에 대한 자세한 통찰력을 제공합니다.

주요 인사이트

제네릭 종양학 의약품 시장 규모(2024E) : 276억 9,000만 달러
예측 시장 규모(2033F) : 489억 달러
세계 시장 성장률(CAGR 2024-2033년) : 6.5%

제네릭 종양학 의약품 시장 - 보고 범위:

제네릭 종양학 의약품은 합리적인 가격과 다양한 암 치료 효과로 건강 관리 분야에서 점점 더 중요 해지고 있습니다. 이러한 의약품은 특히 개발 도상 지역에서 더 많은 사람들이 이용할 수 있도록 함으로써 브랜드 암 치료를 대체하는 필수적인 선택을 제공합니다. 암 이환율의 상승과 비용 효과적인 치료에 대한 요구가 시장의 중요한 촉진요인이 되고 있습니다. 제네릭 종양학 의약품은 화학요법, 면역요법, 표적요법 등 폭넓은 암 치료를 커버하고 있어 시장 성장에 공헌하고 있습니다.

시장 성장 촉진요인:

세계 제네릭 종양학 의약품물 시장의 성장을 뒷받침하는 주요 요인은 여러 가지입니다. 세계의 암 이환율 증가와 합리적인 가격의 치료 옵션에 대한 수요 증가가 중요한 촉진요인이 되고 있습니다. 정부 및 의료기관은 환자의 경제적 부담을 줄이는데 주력하고 있으며, 이는 제네릭 종양학 의약품 수요를 더욱 밀어 올리고 있습니다. 게다가 주요 브랜드 항암제의 특허 만료에 의해 제네릭 의약품의 개발·도입의 기회가 탄생하고 있습니다. 또한 브랜드 의약품을 대체하는 효과적이고 안전한 의약품으로서 제네릭 의약품에 대한 인식과 수용이 높아지고 있는 것도 시장 확대에 기여하고 있습니다.

시장 성장 억제요인:

큰 성장의 가능성에도 불구하고 제네릭 의약품 시장은 문제에 직면하고 있습니다. 주요 장애물 중 하나는 제네릭 의약품의 개발과 승인과 관련된 복잡성과 비용이 높기 때문에 신규 진출기업 시장 진입을 지연시킬 수 있습니다. 또한, 엄격한 규제 요건과 지적 재산권 법률은 특정 지역에서 제네릭 의약품의 입수를 제한할 수 있습니다. 또한, 제네릭 종양학 의약품의 생물학적 동등성 및 효능에 대한 우려는 선발 의약품에 비해 시장 성장에 영향을 미칠 수 있습니다.

시장 기회:

제네릭 종양학 의약품 시장은 특히 저렴한 암 치료에 대한 접근이 우선되는 신흥 시장에서 큰 비즈니스 기회를 제공합니다. 이 지역에서는 건강 관리 인프라의 정비와 제네릭 의약품의 보급을 위한 정부의 이니셔티브에 주목이 모여 시장 성장의 원동력이 될 것으로 기대됩니다. 또한, 의약품 제조 공정의 진보와 비싼 암 치료의 유력한 대안으로 바이오시밀러 의약품의 탐구는 시장 확대의 새로운 길을 제공합니다. 제네릭 의약품 제조업체와 건강 관리 제공업체 간의 전략적 제휴는 이러한 의약품의 가용성과 채용을 더욱 촉진할 것입니다.

이 보고서에서 다루는 주요 질문

세계 제네릭 종양학 의약품 시장을 견인하는 주요 요인은 무엇인가?
제네릭 의약품이 가장 많이 채용되고 있는 암의 유형과 지역은?
규제 프레임워크과 특허 만료은 시장 경쟁 구도에 어떤 영향을 미치는가?
제네릭 종양학 의약품 시장의 주요 기업은 누구이며, 어떤 전략으로 시장에서의 지위를 유지하고 있는가?
세계 제네릭 의약품 시장의 새로운 동향과 장래성은?

영문목차

Persistence Market Research has recently released a comprehensive report on the global Generic Oncology Drugs Market, providing an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges. This report offers detailed insights into the market's structure and growth potential.

Key Insights:

Generic Oncology Drugs Market Size (2024E): USD 27.69 Bn
Projected Market Value (2033F): USD 48.9 Bn
Global Market Growth Rate (CAGR 2024 to 2033): 6.5%

Generic Oncology Drugs Market - Report Scope:

Generic oncology drugs are becoming increasingly critical in the healthcare sector due to their affordability and effectiveness in treating various cancers. These drugs provide an essential alternative to branded cancer treatments, making them accessible to a larger population, especially in developing regions. The rising incidence of cancer, coupled with the need for cost-effective treatments, is a significant driver of the market. Generic oncology drugs cover a broad spectrum of cancer treatments, including chemotherapy, immunotherapy, and targeted therapies, contributing to the market's growth.

Market Growth Drivers:

Several key factors are driving the growth of the global generic oncology drugs market. The increasing prevalence of cancer worldwide and the rising demand for affordable treatment options are crucial drivers. Governments and healthcare organizations are focusing on reducing the financial burden on patients, which is further boosting the demand for generic oncology drugs. Additionally, patent expirations of key branded cancer drugs are creating opportunities for the development and introduction of generic alternatives. The growing awareness and acceptance of generic medicines as effective and safe alternatives to branded drugs are also contributing to market expansion.

Market Restraints:

Despite its significant growth potential, the generic oncology drugs market faces challenges. One of the primary hurdles is the complexity and high cost associated with the development and approval of generic oncology drugs, which can slow down market entry for new players. Furthermore, strict regulatory requirements and intellectual property laws can limit the availability of generics in certain regions. Additionally, concerns related to the bioequivalence and efficacy of generic oncology drugs compared to their branded counterparts can impact market growth.

Market Opportunities:

The generic oncology drugs market presents substantial opportunities, particularly in emerging markets where access to affordable cancer treatment is a priority. The increasing focus on healthcare infrastructure development and government initiatives to promote generic drugs in these regions is expected to drive market growth. Moreover, advancements in drug manufacturing processes and the exploration of biosimilar drugs as a viable alternative for expensive cancer treatments offer new avenues for market expansion. Strategic collaborations between generic drug manufacturers and healthcare providers will further enhance the availability and adoption of these drugs.

Key Questions Answered in the Report:

What are the primary factors driving the global generic oncology drugs market?
Which cancer types are seeing the highest adoption of generic oncology drugs, and in which regions?
How are regulatory frameworks and patent expirations influencing the competitive landscape of this market?
Who are the leading players in the generic oncology drugs market, and what strategies are they using to maintain their market positions?
What are the emerging trends and future prospects in the global generic oncology drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global generic oncology drugs market, such as Teva Pharmaceuticals, Mylan N.V., and Fresenius Kabi, are focusing on innovation, product expansion, and strategic partnerships to strengthen their positions. These companies are heavily investing in research and development to improve drug formulations, expand their oncology portfolios, and ensure compliance with stringent regulatory standards. Collaborations with hospitals and healthcare systems are essential for market penetration, particularly in high-growth regions. As the demand for affordable cancer treatment continues to rise, companies in this space are prioritizing quality, efficacy, and availability to ensure long-term success in the generic oncology drugs market.

Key Companies Profiled:

Bausch Health Companies Inc.
Novartis
Pfizer
GSK
Celgene
Teva Pharmaceuticals
Merck & Company
Aurobindo Pharma
Hikma Pharmaceuticals
Mylan
NATCO Pharma

Key Segments Covered in Generic Oncology Drugs Industry Research

Molecule:

Large Molecule
Small Molecule

Route of Administration:

Oral
Parenteral

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Managed Care Institutions

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Product Adoption Analysis
4.2. Usage Analysis - Key Statistics
4.3. Value Chain Analysis
4.4. Recent Product Approvals/Launches
4.5. Key Regulations - By Region
4.6. Product USP Analysis
4.7. Pipeline Assessment

5. Market Background

5.1. Macroeconomic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Expenditure Overview
- 5.1.3. Global Generic Drugs Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Rising Prevalence of Cancer
- 5.2.2. Increasing Generic Product Approvals
- 5.2.3. Increasing Cases of Cancer Patients
- 5.2.4. Mergers and Acquisitions
- 5.2.5. Regulatory Policies
- 5.2.6. Recent Product Approvals
- 5.2.7. Product Pipeline
- 5.2.8. Advertisements and Endorsements
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Molecule Type
- 6.1.2. By Route of Administration
- 6.1.3. By Distribution Channel
- 6.1.4. By Region
6.2. 2024 Market Scenario

7. Global Generic Oncology Drugs Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Molecule Type

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis, by Molecule Type, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Molecule Type, 2024-2033
- 8.3.1. Large Molecule
- 8.3.2. Small Molecule
8.4. Market Attractiveness Analysis, by Molecule Type

9. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Route of Administration

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
- 9.3.1. Oral
- 9.3.2. Parenteral
9.4. Market Attractiveness Analysis, by Route of Administration

10. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Distribution Channel, 2024-2033
- 10.3.1. Hospital Pharmacy
- 10.3.2. Retail Pharmacy
- 10.3.3. Online Pharmacies
- 10.3.4. Managed Care Institutions
10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Region

11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. East Asia
- 11.3.5. South Asia
- 11.3.6. Oceania
- 11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis, by Region

12. North America Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 12.3.1. By Country
  - 12.3.1.1. U.S.
  - 12.3.1.2. Canada
- 12.3.2. By Molecule Type
- 12.3.3. By Route of Administration
- 12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Molecule Type
- 12.4.3. By Route of Administration
- 12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
- 12.8.1. U.S. Generic Oncology Drugs Market Analysis
  - 12.8.1.1. Introduction
  - 12.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 12.8.1.2.1. By Molecule Type
    - 12.8.1.2.2. By Route of Administration
    - 12.8.1.2.3. By Distribution Channel
- 12.8.2. Canada Generic Oncology Drugs Market Analysis
  - 12.8.2.1. Introduction
  - 12.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 12.8.2.2.1. By Molecule Type
    - 12.8.2.2.2. By Route of Administration
    - 12.8.2.2.3. By Distribution Channel

13. Latin America Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 13.3.1. By Country
  - 13.3.1.1. Mexico
  - 13.3.1.2. Brazil
  - 13.3.1.3. Argentina
  - 13.3.1.4. Rest of Latin America
- 13.3.2. By Molecule Type
- 13.3.3. By Route of Administration
- 13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Molecule Type
- 13.4.3. By Route of Administration
- 13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
- 13.8.1. Mexico Generic Oncology Drugs Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 13.8.1.2.1. By Molecule Type
    - 13.8.1.2.2. By Route of Administration
    - 13.8.1.2.3. By Distribution Channel
- 13.8.2. Brazil Generic Oncology Drugs Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 13.8.2.2.1. By Molecule Type
    - 13.8.2.2.2. By Route of Administration
    - 13.8.2.2.3. By Distribution Channel
- 13.8.3. Argentina Generic Oncology Drugs Market Analysis
  - 13.8.3.1. Introduction
  - 13.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 13.8.3.2.1. By Molecule Type
    - 13.8.3.2.2. By Route of Administration
    - 13.8.3.2.3. By Distribution Channel

14. Europe Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 14.3.1. By Country
  - 14.3.1.1. Germany
  - 14.3.1.2. Italy
  - 14.3.1.3. France
  - 14.3.1.4. U.K.
  - 14.3.1.5. Spain
  - 14.3.1.6. BENELUX
  - 14.3.1.7. Russia
  - 14.3.1.8. Rest of Europe
- 14.3.2. By Molecule Type
- 14.3.3. By Route of Administration
- 14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Molecule Type
- 14.4.3. By Route of Administration
- 14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
- 14.8.1. Germany Generic Oncology Drugs Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.1.2.1. By Molecule Type
    - 14.8.1.2.2. By Route of Administration
    - 14.8.1.2.3. By Distribution Channel
- 14.8.2. Italy Generic Oncology Drugs Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.2.2.1. By Molecule Type
    - 14.8.2.2.2. By Route of Administration
    - 14.8.2.2.3. By Distribution Channel
- 14.8.3. France Generic Oncology Drugs Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.3.2.1. By Molecule Type
    - 14.8.3.2.2. By Route of Administration
    - 14.8.3.2.3. By Distribution Channel
- 14.8.4. U.K. Generic Oncology Drugs Market Analysis
  - 14.8.4.1. Introduction
  - 14.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.4.2.1. By Molecule Type
    - 14.8.4.2.2. By Route of Administration
    - 14.8.4.2.3. By Distribution Channel
- 14.8.5. Spain Generic Oncology Drugs Market Analysis
  - 14.8.5.1. Introduction
  - 14.8.5.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.5.2.1. By Molecule Type
    - 14.8.5.2.2. By Route of Administration
    - 14.8.5.2.3. By Distribution Channel
- 14.8.6. BENELUX Generic Oncology Drugs Market Analysis
  - 14.8.6.1. Introduction
  - 14.8.6.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.6.2.1. By Molecule Type
    - 14.8.6.2.2. By Route of Administration
    - 14.8.6.2.3. By Distribution Channel
- 14.8.7. Russia Generic Oncology Drugs Market Analysis
  - 14.8.7.1. Introduction
  - 14.8.7.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.7.2.1. By Molecule Type
    - 14.8.7.2.2. By Route of Administration
    - 14.8.7.2.3. By Distribution Channel

15. East Asia Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. China
  - 15.3.1.2. Japan
  - 15.3.1.3. South Korea
- 15.3.2. By Molecule Type
- 15.3.3. By Route of Administration
- 15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Molecule Type
- 15.4.2. By Route of Administration
- 15.4.3. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
- 15.8.1. China Generic Oncology Drugs Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.1.2.1. By Molecule Type
    - 15.8.1.2.2. By Route of Administration
    - 15.8.1.2.3. By Distribution Channel
- 15.8.2. Japan Generic Oncology Drugs Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.2.2.1. By Molecule Type
    - 15.8.2.2.2. By Route of Administration
    - 15.8.2.2.3. By Distribution Channel
- 15.8.3. South Korea Generic Oncology Drugs Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.3.2.1. By Molecule Type
    - 15.8.3.2.2. By Route of Administration
    - 15.8.3.2.3. By Distribution Channel

16. South Asia Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. India
  - 16.3.1.2. Indonesia
  - 16.3.1.3. Malaysia
  - 16.3.1.4. Thailand
  - 16.3.1.5. Rest of South Asia
- 16.3.2. By Molecule Type
- 16.3.3. By Route of Administration
- 16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Molecule Type
- 16.4.3. By Route of Administration
- 16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
- 16.8.1. India Generic Oncology Drugs Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.1.2.1. By Molecule Type
    - 16.8.1.2.2. By Route of Administration
    - 16.8.1.2.3. By Distribution Channel
- 16.8.2. Indonesia Generic Oncology Drugs Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.2.2.1. By Molecule Type
    - 16.8.2.2.2. By Route of Administration
    - 16.8.2.2.3. By Distribution Channel
- 16.8.3. Malaysia Generic Oncology Drugs Market Analysis
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.3.2.1. By Molecule Type
    - 16.8.3.2.2. By Route of Administration
    - 16.8.3.2.3. By Distribution Channel
- 16.8.4. Thailand Generic Oncology Drugs Market Analysis
  - 16.8.4.1. Introduction
  - 16.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.4.2.1. By Molecule Type
    - 16.8.4.2.2. By Route of Administration
    - 16.8.4.2.3. By Distribution Channel

17. Oceania Generic Oncology Drugs Market 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. Australia
  - 17.3.1.2. New Zealand
- 17.3.2. By Molecule Type
- 17.3.3. By Route of Administration
- 17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Molecule Type
- 17.4.3. By Route of Administration
- 17.4.4. By Distribution Channel
17.5. Key Market Participants - Intensity Mapping
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
- 17.8.1. Australia Generic Oncology Drugs Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.1.2.1. By Molecule Type
    - 17.8.1.2.2. By Route of Administration
    - 17.8.1.2.3. By Distribution Channel
- 17.8.2. New Zealand Generic Oncology Drugs Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.2.2.1. By Molecule Type
    - 17.8.2.2.2. By Route of Administration
    - 17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

18.1. Introduction
18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 18.3.1. By Country
  - 18.3.1.1. GCC Countries
  - 18.3.1.2. Turkey
  - 18.3.1.3. South Africa
  - 18.3.1.4. North Africa
  - 18.3.1.5. Rest of Middle East and Africa
- 18.3.2. By Molecule Type
- 18.3.3. By Route of Administration
- 18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Molecule Type
- 18.4.3. By Route of Administration
- 18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
- 18.8.1. GCC Countries Generic Oncology Drugs Market Analysis
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.8.1.2.1. By Molecule Type
    - 18.8.1.2.2. By Route of Administration
    - 18.8.1.2.3. By Distribution Channel
- 18.8.2. Turkey Generic Oncology Drugs Market Analysis
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.8.2.2.1. By Molecule Type
    - 18.8.2.2.2. By Route of Administration
    - 18.8.2.2.3. By Distribution Channel
- 18.8.3. South Africa Generic Oncology Drugs Market Analysis
  - 18.8.3.1. Introduction
  - 18.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.8.3.2.1. By Molecule Type
    - 18.8.3.2.2. By Route of Administration
    - 18.8.3.2.3. By Distribution Channel
- 18.8.4. North Africa Generic Oncology Drugs Market Analysis
  - 18.8.4.1. Introduction
  - 18.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.8.4.2.1. By Molecule Type
    - 18.8.4.2.2. By Route of Administration
    - 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

19.1. Market Analysis, by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Concentration
19.4. Market Presence Analysis

20. Competition Analysis

20.1. Competition Dashboard
20.2. Competition Deep Dive
- 20.2.1. Bausch Health Companies Inc.
  - 20.2.1.1. Overview
  - 20.2.1.2. Product Portfolio
  - 20.2.1.3. Sales Footprint
  - 20.2.1.4. Key Financials
  - 20.2.1.5. SWOT Analysis
  - 20.2.1.6. Strategy Overview
    - 20.2.1.6.1. Marketing Strategy
    - 20.2.1.6.2. Product Strategy
    - 20.2.1.6.3. Channel Strategy
- 20.2.2. Novartis
  - 20.2.2.1. Overview
  - 20.2.2.2. Product Portfolio
  - 20.2.2.3. Sales Footprint
  - 20.2.2.4. Key Financials
  - 20.2.2.5. SWOT Analysis
  - 20.2.2.6. Strategy Overview
    - 20.2.2.6.1. Marketing Strategy
    - 20.2.2.6.2. Product Strategy
    - 20.2.2.6.3. Channel Strategy
- 20.2.3. Pfizer
  - 20.2.3.1. Overview
  - 20.2.3.2. Product Portfolio
  - 20.2.3.3. Sales Footprint
  - 20.2.3.4. Key Financials
  - 20.2.3.5. SWOT Analysis
  - 20.2.3.6. Strategy Overview
    - 20.2.3.6.1. Marketing Strategy
    - 20.2.3.6.2. Product Strategy
    - 20.2.3.6.3. Channel Strategy
- 20.2.4. GSK
  - 20.2.4.1. Overview
  - 20.2.4.2. Product Portfolio
  - 20.2.4.3. Sales Footprint
  - 20.2.4.4. Key Financials
  - 20.2.4.5. SWOT Analysis
  - 20.2.4.6. Strategy Overview
    - 20.2.4.6.1. Marketing Strategy
    - 20.2.4.6.2. Product Strategy
    - 20.2.4.6.3. Channel Strategy
- 20.2.5. Celgene
  - 20.2.5.1. Overview
  - 20.2.5.2. Product Portfolio
  - 20.2.5.3. Sales Footprint
  - 20.2.5.4. Key Financials
  - 20.2.5.5. SWOT Analysis
  - 20.2.5.6. Strategy Overview
    - 20.2.5.6.1. Marketing Strategy
    - 20.2.5.6.2. Product Strategy
    - 20.2.5.6.3. Channel Strategy
- 20.2.6. Teva Pharmaceuticals
  - 20.2.6.1. Overview
  - 20.2.6.2. Product Portfolio
  - 20.2.6.3. Sales Footprint
  - 20.2.6.4. Key Financials
  - 20.2.6.5. SWOT Analysis
  - 20.2.6.6. Strategy Overview
    - 20.2.6.6.1. Marketing Strategy
    - 20.2.6.6.2. Product Strategy
    - 20.2.6.6.3. Channel Strategy
- 20.2.7. Merck & Company
  - 20.2.7.1. Overview
  - 20.2.7.2. Product Portfolio
  - 20.2.7.3. Sales Footprint
  - 20.2.7.4. Key Financials
  - 20.2.7.5. SWOT Analysis
  - 20.2.7.6. Strategy Overview
    - 20.2.7.6.1. Marketing Strategy
    - 20.2.7.6.2. Product Strategy
    - 20.2.7.6.3. Channel Strategy
- 20.2.8. Aurobindo Pharma
  - 20.2.8.1. Overview
  - 20.2.8.2. Product Portfolio
  - 20.2.8.3. Sales Footprint
  - 20.2.8.4. Key Financials
  - 20.2.8.5. SWOT Analysis
  - 20.2.8.6. Strategy Overview
    - 20.2.8.6.1. Marketing Strategy
    - 20.2.8.6.2. Product Strategy
    - 20.2.8.6.3. Channel Strategy
- 20.2.9. Hikma Pharmaceuticals
  - 20.2.9.1. Overview
  - 20.2.9.2. Product Portfolio
  - 20.2.9.3. Sales Footprint
  - 20.2.9.4. Key Financials
  - 20.2.9.5. SWOT Analysis
  - 20.2.9.6. Strategy Overview
    - 20.2.9.6.1. Marketing Strategy
    - 20.2.9.6.2. Product Strategy
    - 20.2.9.6.3. Channel Strategy
- 20.2.10. Mylan
  - 20.2.10.1. Overview
  - 20.2.10.2. Product Portfolio
  - 20.2.10.3. Sales Footprint
  - 20.2.10.4. Key Financials
  - 20.2.10.5. SWOT Analysis
  - 20.2.10.6. Strategy Overview
    - 20.2.10.6.1. Marketing Strategy
    - 20.2.10.6.2. Product Strategy
    - 20.2.10.6.3. Channel Strategy
- 20.2.11. NATCO Pharma
  - 20.2.11.1. Overview
  - 20.2.11.2. Product Portfolio
  - 20.2.11.3. Sales Footprint
  - 20.2.11.4. Key Financials
  - 20.2.11.5. SWOT Analysis
  - 20.2.11.6. Strategy Overview
    - 20.2.11.6.1. Marketing Strategy
    - 20.2.11.6.2. Product Strategy
    - 20.2.11.6.3. Channel Strategy

한글목차

목차

제1장 주요 요약

제2장 시장 개요

제3장 주요 시장 동향

제4장 중요 성공 요인

제5장 시장 배경

제6장 COVID-19 위기 분석

제7장 세계 제네릭 종양학 의약품 시장 수요(금액, 10억 달러) 분석

제8장 분자 유형별 : 세계의 제네릭 종양학 의약품 시장 분석

제9장 투여 경로별 : 세계의 제네릭 종양학 의약품 시장 분석

제10장 유통 채널별 : 세계의 제네릭 종양학 의약품 시장 분석

제11장 지역별 : 세계의 제네릭 종양학 의약품 시장 분석

제12장 북미의 제네릭 종양 약 시장 분석

제13장 라틴아메리카의 제네릭 종양학 의약품물 시장 분석

제14장 유럽의 제네릭 종양 약 시장 분석

제15장 동아시아 제네릭 종양 약 시장 분석

제16장 남아시아 제네릭 종양 약 시장 분석

제17장 오세아니아의 제네릭 종양 약 시장

제18장 중동 및 아프리카 제네릭 종양학 의약품 시장 분석

제19장 시장 구조 분석

제20장 경쟁 분석

제21장 사용된 전제조건과 약어

제22장 조사 방법